Medical expert of the article
New publications
Preparations
Neurovin
Last reviewed: 04.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Neurovin is a psychostimulant with nootropic activity.
Indications Neurovina
It is used in neurology - various types of cerebrovascular disease: conditions associated with the transfer of disorders of intracerebral blood flow (stroke), vascular dementia, VBI, encephalopathy of a hypertensive or post-traumatic nature, and cerebral atherosclerosis. The drug helps to reduce neurological and mental manifestations in cerebrovascular disease.
It can be prescribed for ophthalmological procedures - in case of chronic diseases of the retina and vascular membranes.
It is also used in otolaryngology – for presbycusis in its perceptual form, tinnitus and Meniere's syndrome.
Release form
The drug is released in tablets, in the amount of 10 pieces in a cell package, 3 packages in a pack.
Pharmacodynamics
Vinpocetine is a compound with a combined effect, positively affecting cerebral metabolic processes and improving blood supply to the brain. In addition, the component improves rheological blood parameters.
Vinpocetine has neuroprotective activity: it reduces the negative impact of cytotoxic symptoms caused by stimulating amino acids. The drug slows down the activity of potential-dependent N+/- and Ca2+/-channels, and along with this, the NMDA endings with AMPA. It also potentiates the neuroprotective activity of adenosine.
Neurovin stimulates the activity of cerebral metabolic processes: increases glucose and O2 uptake, as well as the consumption of these components by brain tissues. Increases the resistance of the brain to hypoxia, increases the volume of glucose transferred through the BBB - an important and exclusive energy source for the brain, moves the conduct of glucose metabolism to a more suitable energetic aerobic pathway, selectively slows down the action of the Ca2+/-calmodulin-dependent enzyme cGMP-PDE and increases the values of cAMP together with cGMP inside the brain.
Increases ATP values, and in addition, the ratio of ATP elements with AMP, potentiates the metabolism of serotonin with noradrenaline occurring inside the brain and stimulates the ascending activity of the noradrenergic system. Along with this, it has an antioxidant effect and a cerebroprotective effect, developing as a result of the action of all the above factors.
Vinpocetine helps improve cerebral microcirculation: slows down platelet aggregation, reduces pathologically increased blood viscosity, increases erythrocyte deformation capacity, and slows down adenosine uptake processes. In addition, it improves O2 movement processes within tissues, weakening the affinity of B2 for erythrocytes.
The drug selectively increases cerebral blood flow: it increases the cerebral fraction of the produced cardiac output and reduces vascular resistance inside the brain, without affecting the properties of the general circulation (cardiac output, OPSS, blood pressure and pulse rate). At the same time, its use leads to improved blood flow into damaged (but not yet necrotic) ischemic zones with a low perfusion level.
Pharmacokinetics
Absorption.
Vinpocetine is absorbed at a high rate, reaching plasma Cmax values after 1 hour after oral administration. Most of the element is absorbed through the proximal parts of the gastrointestinal tract. The substance does not participate in metabolic processes when passing through the intestinal wall.
Distribution processes.
The highest levels of the substance were observed in the gastrointestinal tract and liver. The Cmax level inside the tissues is recorded after 2-4 hours from the moment of drug administration. The values of the radioactive label inside the brain correspond to blood levels.
Synthesis with blood protein is 66%. Bioavailability values after internal use are 7%. The drug clearance rate (66.7 l/hour) in blood plasma is higher than the liver values (50 l/hour), from which it can be concluded that the component is not metabolized in the liver.
Exchange processes.
The main metabolic element is the substance VKA, which is formed from 25-30% of the drug. When taken orally, the AUC values of VKA are twice as high as those after intravenous injection, which suggests that VKA is formed during presystemic metabolism of vinpocetine.
Excretion.
After repeated oral administration of 5 and 10 mg of the substance, linear therapeutic kinetics are observed. The half-life of the drug is 4.83±1.29 hours. Excretion of the majority of the drug occurs through the intestines and kidneys in a ratio of 40/60%.
Dosing and administration
The standard dosage is 5-10 mg of the drug 3 times a day (15-30 mg per day). The tablets should be taken after meals.
The duration of the therapeutic cycle is selected individually by the attending physician.
[ 1 ]
Use Neurovina during pregnancy
It is prohibited to prescribe Neurovin during breastfeeding or pregnancy.
Contraindications
Contraindicated for use in case of severe intolerance to the active ingredient or auxiliary elements of the medication.
Side effects Neurovina
Side effects include:
- lesions of the lymph and blood system: thrombocytopenia or leukopenia are occasionally observed. Erythrocyte agglutination or anemia is occasionally observed;
- immune disorders: severe sensitivity occurs occasionally;
- problems with nutritional and metabolic processes: sometimes hypercholesterolemia develops. Anorexia, loss of appetite and diabetes mellitus are occasionally observed;
- Mental disorders: sleep problems, insomnia and anxiety occasionally occur. Depression or a feeling of euphoria develops occasionally;
- damage to the nervous system function: headaches, dysgeusia, amnesia, dizziness, as well as a feeling of drowsiness, hemiparesis and a state of stupor occasionally occur. Convulsions or tremors appear sporadically;
- visual impairment: swelling of the nipple in the area of the optic nerve is occasionally observed. Isolated cases of conjunctival hyperemia;
- disorders associated with the activity of the labyrinth and auditory organs: vertigo sometimes occurs. Hypo- or hyperacusis, as well as tinnitus, occasionally appear;
- problems with the cardiovascular system: tachycardia, myocardial infarction or ischemia, palpitations, bradycardia with extrasystole and coronary heart disease are occasionally observed. Atrial fibrillation or simply arrhythmia develops occasionally;
- vascular disorders: blood pressure values sometimes increase. Hot flashes or thrombophlebitis occasionally occur and blood pressure values decrease. Blood pressure fluctuations may develop sporadically;
- Gastrointestinal tract dysfunction: sometimes dryness of the oral mucosa, abdominal discomfort and nausea appear. Rarely, dyspepsia, pain in the abdominal area, vomiting, constipation and diarrhea occur. Stomatitis or dysphagia develops isolated cases;
- disorders affecting the subcutaneous layers and epidermis: occasionally itching, erythema, rashes, urticaria or hyperhidrosis appear. Dermatitis develops occasionally;
- systemic lesions: occasionally there is a feeling of weakness or heat and asthenia. Isolated cases - hypothermia or discomfort in the sternum;
- Diagnostic and laboratory test results: blood pressure may sometimes decrease. Occasionally, blood triglyceride levels or blood pressure may increase, eosinophil counts may increase or decrease, depression in the ST segment of the ECG may develop, and liver enzyme activity may change. Occasionally, red blood cell counts or the PT index may decrease, white blood cell counts may decrease or increase, and weight may increase.
Interactions with other drugs
The combination of vinpocetine and β-blockers (e.g. pinodolol or cloranolol), and also glibenclamide, clopamide with digoxin, hydrochlorothiazide and acenocoumarol does not lead to any therapeutic interaction. Rarely, a weak additional effect was noted when combined with α-methyldopa, which is why blood pressure values should be constantly monitored when using these medications.
It is necessary to be very careful when combining Neurovin with substances that affect the functioning of the central nervous system, and also when administering it simultaneously with an anticoagulant or antiarrhythmic treatment cycle.
Storage conditions
Neurovin must be stored in a dry place, out of the reach of small children. Temperature indicators are a maximum of 25°C.
Shelf life
Neurovin can be used for a period of 36 months from the date of manufacture of the pharmaceutical substance.
Attention!
To simplify the perception of information, this instruction for use of the drug "Neurovin" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.